The clinical significance of tumor infiltrating lymphoctyes in breast cancer: Does subtype matter?

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Krell, Jonathan ^a   Frampton, Adam E ^a   Stebbing, Justin ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cancer; Immunobiology; Tumor infiltrating lymphocytes

Indexed keywords

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; HUMAN; IMMUNE STATUS; IMMUNOBIOLOGY; IMMUNOGENICITY; IMMUNOMODULATION; NOTE; REGULATORY T LYMPHOCYTE; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; BREAST TUMOR; DISEASE COURSE; EDITORIAL; FEMALE; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING;

EID: 84859170032     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-135     Document Type: Note

References (17)

1. Caprioli RM. Deciphering protein molecular signatures in cancer tissues to aid in diagnosis, prognosis, and therapy. Cancer Res 2005, 65(23):10642-10645. 10.1158/0008-5472.CAN-04-3581, 16322204.
2. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature reviews Cancer 2006, 6(11):857-866. 10.1038/nrc1997, 17060945.
3. Pandolfi F, Cianci R, Pagliari D, Casciano F, Bagala C, Astone A, Landolfi R, Barone C. The Immune Response to Tumors as a Tool toward Immunotherapy. Clinical & developmental immunology 2011, 2011:894704.
4. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011, 29(15):1949-1955. 10.1200/JCO.2010.30.5037, 21483002.
5. Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A. CD4 + CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004, 112(3):258-267. 10.1016/j.clim.2004.04.003, 15308119.
6. Murakami M, Sakamoto A, Bender J, Kappler J, Marrack P. CD25 + CD4+ T cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci USA 2002, 99(13):8832-8837. 10.1073/pnas.132254399, 124384, 12084927.
7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964. 10.1126/science.1129139, 17008531.
8. Oble DA, Loewe R, Yu P, Mihm MC. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer immunity: a journal of the Academy of Cancer Immunology 2009, 9:3.
9. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003, 9(2):606-612.
10. Nedergaard BS, Ladekarl M, Thomsen HF, Nyengaard JR, Nielsen K. Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. Br J Cancer 2007, 97(8):1135-1138. 10.1038/sj.bjc.6604001, 2360435, 17940503.
11. Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, Pudelko M, Szynglarewicz B, Szelachowska J, Zolnierek A, et al. The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer research 2009, 29(7):2445-2451.
12. Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO, Lee AH. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 2009, 45(10):1780-1787. 10.1016/j.ejca.2009.02.014, 19286369.
13. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, Tagliabue E, Balsari A. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009, 27(11):1746-1752. 10.1200/JCO.2008.17.9036, 19255331.
14. Horlock C, Stott B, Dyson PJ, Morishita M, Coombes RC, Savage P, Stebbing J. The effects of trastuzumab on the CD4 + CD25 + FoxP3+ and CD4 + IL17A + T-cell axis in patients with breast cancer. Br J Cancer 2009, 100(7):1061-1067. 10.1038/sj.bjc.6604963, 2670001, 19277040.
15. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010, 28(1):105-113. 10.1200/JCO.2009.23.7370, 19917869.
16. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988, 319(25):1676-1680. 10.1056/NEJM198812223192527, 3264384.
17. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999, 17(8):2521-2529.